Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Department of Pathology and Laboratory Medicine, |
RCV000503369 | SCV000592953 | pathogenic | Lynch syndrome | criteria provided, single submitter | clinical testing | ||
Invitae | RCV003593975 | SCV004294440 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2023-06-15 | criteria provided, single submitter | clinical testing | This variant disrupts the MLH1 interaction domain of the PMS2 protein, which has been shown to be critical for PMS2-MLH1 dimerization (PMID: 10037723), and therefore mismatch repair activity (PMID: 16338176, 20533529). While functional studies have not been performed to directly test the effect of this variant on PMS2 protein function, this suggests that disruption of this region of the protein is causative of disease. ClinVar contains an entry for this variant (Variation ID: 434032). This premature translational stop signal has been observed in individual(s) with clinical features of constitutional mismatch repair deficiency syndrome (PMID: 24440087). The frequency data for this variant in the population databases (gnomAD) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This sequence change creates a premature translational stop signal (p.Thr820Asnfs*4) in the PMS2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 43 amino acid(s) of the PMS2 protein. This variant disrupts a region of the PMS2 protein in which other variant(s) (p.Asn823Lysfs*63) have been determined to be pathogenic (PMID: 31992580; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |